Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.42 |
| ▸ | JAK1 | P23458 | 11/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523407 | 0.89 | JAK2 (0.42) | JAK2JAK1GPR119 | |
| SCHEMBL3530140 | 0.86 | GPR119 (0.43) | JAK2JAK1GPR119TSHRALOX15 | |
| SCHEMBL13543115 | 0.85 | JAK2 (0.46) | JAK2JAK1GPR119TSHRALOX15 | |
| SCHEMBL16553939 | 0.85 | MEN1 (0.46) | JAK2JAK1TSHRALOX15ATM | |
| SCHEMBL3529491 | 0.83 | GPR119 (0.43) | JAK2JAK1GPR119TSHRALOX15 | |
| SCHEMBL30479343 | 0.83 | GPR119 (0.43) | JAK2JAK1GPR119TSHRALOX15 | |
| SCHEMBL16565388 | 0.81 | TSHR (0.53) | JAK2JAK1GPR119TSHRALOX15 | |
| SCHEMBL3528504 | 0.80 | NPC1 (0.47) | JAK2JAK1TSHRALOX15ATM | |
| SCHEMBL3526813 | 0.79 | TSHR (0.44) | JAK2JAK1GPR119TSHRALOX15 | |
| SCHEMBL3533009 | 0.79 | JAK2 (0.48) | JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | JAK2 2862/4885JAK1 2938/4885GPR119 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.